The two-stage single arm open label study in combination with gemcitabine enrolled nearly 35 patients to study the overall survival rate.
The study is said to have met its end point.
Following Phase I clinical trial, it was found that Archexin has a good human safety profile and its only side effect is fatigue.
The company expects to report preliminary results in the first half of 2012
Archexin, an Akt protein kinase inhibitor, inhibits cancer cell survival and proliferation, angiogenesis and drug resistance
The drug has FDA Orphan drug designation for five different cancer types, including renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.